Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Have Conflicting Sentiments on These Financial Companies: T Rowe Price (TROW) and Metlife (MET)

Tipranks - Fri Feb 6, 9:38AM CST

Analysts have been eager to weigh in on the Financial sector with new ratings on T Rowe Price (TROWResearch Report) and Metlife (METResearch Report).

Claim 50% Off TipRanks Premium

T Rowe Price (TROW)

In a report released today, Craig Siegenthaler from Bank of America Securities maintained a Sell rating on T Rowe Price. The company’s shares closed last Thursday at $94.01, close to its 52-week low of $91.10.

According to TipRanks.com, Siegenthaler is a 5-star analyst with an average return of 20.1% and a 62.8% success rate. Siegenthaler covers the Financial sector, focusing on stocks such as Figure Technology Solutions, Inc. Class A, Intercontinental Exchange, and Apollo Global Management. ;'>

T Rowe Price has an analyst consensus of Moderate Sell, with a price target consensus of $106.00, which is a 10.2% upside from current levels. In a report released today, Barclays also maintained a Sell rating on the stock with a $94.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Metlife (MET)

Bank of America Securities analyst Joshua Shanker maintained a Buy rating on Metlife today. The company’s shares closed last Thursday at $78.59.

According to TipRanks.com, Shanker is a 5-star analyst with an average return of 8.0% and a 60.5% success rate. Shanker covers the Financial sector, focusing on stocks such as Neptune Insurance Holdings, Inc. Class A, American International Group, and Corebridge Financial, Inc. ;'>

Currently, the analyst consensus on Metlife is a Strong Buy with an average price target of $93.91, implying a 18.1% upside from current levels. In a report released today, UBS also maintained a Buy rating on the stock with a $98.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.